Skip to main content
. 2024 Jan 11;29(2):105–135. doi: 10.1111/resp.14656

FIGURE 2.

FIGURE 2

Pathogenic pathways of IPF and potential clinical trial targets. Current (blue) and proposed (green) molecules assessed in clinical trials for the treatment of idiopathic pulmonary fibrosis. Modulators (→) and inhibitors (┬) are shown directed at different components of the fibrosis pathway. Created with Biorender.com.